Advancements and Insights in Non–Muscle-Invasive Bladder Cancer: Emerging PD-1/PD-L1 Inhibitors : Episode 5
Opinion
Video
Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC
Key Takeaways
- Urologists need oncologists to provide systemic therapy insights and manage immune-related adverse events in combination therapy.
- Oncologists rely on urologists for expertise in local disease management and patient selection for combination therapy.
Panelists discuss how urologists and oncologists must collaborate to improve outcomes for high-risk non–muscle-invasive bladder cancer (NMIBC) patients receiving combination therapy with PD-1/PD-L1 inhibitors and BCG, emphasizing the need for clear communication and coordinated care strategies.
Video Player is loading.
Video content above is prompted by the following:
- What do urologists need from oncologists, and vice versa, in improving outcomes for high-risk non–muscle-invasive bladder cancer patients for combination therapy with PD-1/PD-L1 inhibitors plus BCG?
Related Videos
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC
Exploring Emerging Data in NMIBC
Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management
Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC
Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy
Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors
Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC
NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes
Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging
Related Content
